Clinical Observation On The Treatment Of Patients With HFrEF Of Heart-kidney Yang Deficiency By Shacubatril Valsartan Sodium Tablets Combined With Shenqi Jianxin Prescription

Purpose:Chronic heart failure is the terminal stage of various heart diseases.At present,exploring new effective treatment options for chronic heart failure has always been the focus of clinical treatment research.Shacubatril Valsartan Sodium Tablets is the first Angiotensin receptor neprilysin inhibitor,a new type of treatment for chronic heart failure.Many pharmacological and clinical studies have shown that Shacubatril Valsartan Sodium Tablets have a good therapeutic effect on chronic heart failure.With the development of modern medicine,people’s cognition of CHF has made great progress.But for now,CHF pathogenesis is not fully understood,high mortality of clinical problems to be solved.Non-drug therapy has limited clinical indications and is expensive,so it is not easy to be accepted by patients.Traditional Chinese medicine conducts dialectical treatment based on the patient’s clinical symptoms and tongue and pulse performance.It can further improve the symptoms and signs of CHF patients on the basis of conventional treatment with western medicine,and has the characteristics of low price,safety and effectiveness.This article will observe the effects of Shacubatril Valsartan Sodium Tablets combined with Shenqi Jianxin Prescription on clinical symptoms,quality of life,left ventricular structure and function,TCM syndromes,and6-minute walking distance in patients with HFrEF of Heart-Kidney Yang Deficiency during the treatment.We strive to find the possible mechanism of traditional Chinese medicine in the treatment of chronic heart failure.Method:From January 2020 to September 2020,80 outpatients and inpatients patients with chronic HFrEF of heart-kidney yang deficiency and NYHA Heart function classification between Ⅱ-Ⅲ were selected,and randomly divided into two groups in the Cardiology Department of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine.The control group received Shacubatril Valsartan Sodium Tablets,β-receptor blocker,aldosterone receptor antagonist.The treatment group received Shenqi Jianxin Decoction on the basis of the control group.All patients were followed up for six months.We will compare the changes of NYHA Heart function classification,Suda quality of life survey,6-min walk distance,echocardiography(LVEF,LVEDD),NT-Pro BNP and TCM syndrome points before and after treatment.Result:1.After comparison,the differences in age,gender,BMI,underlying diseases,and duration of the disease between the two groups were statistically significant,P>0.05.2.NYHA Heart function classification: Before treatment,the difference in NYHA heart function classification between the two groups of patients was not statistically significant,P>0.05;after treatment,the curative effect of the treatment group was better than that of the control group,P<0.05.And there was a significant difference in the total effective rate between the two groups.The total effective rate in the treatment group was 86.11%,and the total effective rate in the control group was 75.68%.3.6 minutes walk: Before treatment,there was no statistically significant difference in 6MWT between the two groups of patients,P>0.05;after active treatment,the 6MWT of the two groups of patients increased compared with before,P<0.05;and the effect of Shenqi Jianxin Prescription in improving 6MWT was more significant than that in the control group,P<0.05.4.Echocardiography: Before treatment,there was no significant difference between the two groups of patients in LVEF and LVEDD,P>0.05;After active treatment of the two groups of patients,LVEF increased compared with before,P<0.05;Moreover,the oral Shenqi Jianxin Decoction group had better curative effect in improving LVEF,P<0.05.There was no significant difference between LVEDD after treatment and before treatment,P>0.05.5.NT-Pro BNP: Before treatment,there was no statistically significant difference in NT-Pro BNP between the two groups of patients,P>0.05;after treatment,the NT-Pro BNP of the two groups of patients was lower than before treatment,P<0.05;and the reduction of NT-pro BNP in Shenqi Jianxin Prescription group was more significant,P<0.05.6.TCM Syndrome Points: Before treatment,there was no statistically significant difference in TCM syndrome points between the two groups of patients,P>0.05;after active treatment of the two groups of patients,the scores of TCM syndromes were lower than before,P < 0.05;and the TCM syndrome score of Shenqi Jianxin Prescription group was significantly lower than that of the control group,P<0.05.7.Suda Heart Failure Quality of Life Score: Before treatment,there was no statistically significant difference in the quality of life scores between the two groups of patients,P>0.05;after active treatment,the quality of life scores of the two groups of patients were lower than before,P<0.05;and the Shenqi Jianxin Prescription group was significantly better than the control group in improving the quality of life,P<0.05.8.Safety evaluation: During the treatment,no patients had adverse reactions such as hypotension,liver and kidney damage,electrolyte imbalance and so on.Conclusion: The clinical effect of Shacubatril Valsartan Sodium Tablets combined with Shenqi Jianxin prescription on HFrEF patients with heart and kidney yang deficiency is definite.It can effectively improve patients’ symptoms,improve quality of life,and also can improve left ventricular ejection fraction and TCM syndrome scores,increase 6-minute walking distance.The most important thing is that it has high security.